IOL Chemicals to launch API business to US market

20 Jul 2015 Evaluate

IOL Chemicals and Pharmaceuticals (IOLCP) has received from US Food and Drug Administration (USFDA), Establishment Inspection Report after successful inspection of its Ibuprofen manufacturing facility situated at Barnala, Punjab, India.

Post this approval, the company will be able to garner additional business for its flagship API Ibuprofen in World's largest pharma market-USA. This will result into higher value added export turnover and higher margins.

The company’s manufacturing facility already holds CEP certification (Certificate of Suitability) for its products Ibuprofen, Metformin Hydrochloride & Lamotrigine from European Directorate for the Quality of Medicines & HealthCare (EDQM) authorities, Council of Europe, France. The said facility at Barnala has also been approved by ANVISA Brazil, WHO & MOH Japan.

These approvals will help the company to build and sustaining the growth by its API business in coming years, being the only integrated player globally, by exploring the higher value added regulated markets.

IOL Chem & Pharma Share Price

81.50 -1.44 (-1.74%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×